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Introduction {#sec1.1}
------------

2019 marks the 20th anniversary of the definitive description of plasmacytoid dendritic cells (pDCs) as a unique cell type by the Liu and Colonna groups ([@bib29], [@bib148]). This description was based on extensive prior research by multiple groups (reviewed in [@bib37], [@bib100]) that collectively defined the essential properties of pDCs: secretory "plasmacytoid" morphology akin to that of plasma cells, rapid and massive production of type I interferons (IFN-I) in response to viruses, and the ability to differentiate into conventional dendritic cells (cDCs) *in vitro*. The last 20 years produced extraordinary insights into all aspects of pDC biology, including their development, mechanism of activity, and role in the immune system. At the same time, this progress brought us to fundamental unanswered questions about the role and mechanism of pDC function. Solving these questions would hasten the translation of accumulated knowledge into clinical applications focused on pDCs.

Accordingly, the goal of this review is both to summarize the current understanding and to highlight the gaps in our knowledge of pDC biology. Rather than an extensive listing of all pDC-related topics, it focuses on several key areas and concepts and also emphasizes the studies of the last several years that have not been covered in the previous reviews. I sincerely apologize to the researchers whose important original contributions could not be cited due to the limited time frame and scope of this review.

Development and Transcriptional Regulation of pDCs {#sec1.2}
--------------------------------------------------

pDCs primarily reside in and recirculate through lymphoid organs, where they typically comprise 0.1%--0.5% of nucleated cells. They have the round morphology of a secretory lymphocyte and express low levels of MHC class II that can be upregulated upon activation. pDCs express high levels of endosomal nucleic acid-sensing Toll-like receptors (TLRs) TLR7 and TLR9, which recognize single-stranded RNA and unmethylated CpG motif-containing DNA, respectively. pDCs respond to these nucleic acids with massive secretion of IFN-I, which commences within 1--3 h and involves IFN-β and most IFN-α subtypes. pDCs also produce type III interferon (IFN-λ or IL-28/IL-29) and additional cytokines (e.g., TNF-α) and chemokines ([@bib62], [@bib127], [@bib155]). The speed, magnitude, and broad spectrum of interferon production by pDCs are reflected in the original definition of these cells as "natural interferon-producing cells" ([@bib37], [@bib100]). This and other key genetic and functional features of pDCs are shared between humans and mice ([@bib41], [@bib70]), highlighting evolutionary conservation of this immune cell type. This review will primarily focus on IFN-I production as the most prominent, unique, and well-established feature of pDCs, even though other aspects of pDC function such as antigen presentation are undoubtedly important ([@bib168]).

pDCs are continuously produced in the bone marrow (BM) and emerge as mature cells into the periphery, where they remain non-proliferative and have a relatively short lifespan of several days ([@bib181]). Similar to cDCs, pDC express cytokine receptor Flt3 (CD135) and are strictly dependent on its ligand Flt3L for their development. Conversely, Flt3L in the absence of other signals is sufficient to drive the development of pDCs and cDCs from myeloid and lymphoid progenitors ([@bib138]), consistent with the potential of both progenitor types to produce pDCs *in vivo* ([@bib146]). The myeloid pathway to pDCs includes a potential common dendritic cell (DC) progenitor (CDP) ([@bib115], [@bib119]) and pDC-biased DC progenitors ([@bib120], [@bib142]). The identity of lymphoid progenitors of pDCs has been recently studied in greater detail ([@bib72], [@bib128]). Notably, relative rarity and quiescence of pDC-committed lymphoid progenitors ([@bib128]) are not consistent with these cells being a major source of much more abundant pDCs. Indeed, lineage tracing using the CDP marker Csf1r showed that the vast majority of pDCs became labeled ([@bib103]); in contrast, recently deposited results of B cell progenitor tracing suggest that a minor distinct population of pDCs is derived from these progenitors ([@bib50]). Furthermore, pDCs develop from stem cells *in vivo* with the same kinetics as myeloid cells including cDCs ([@bib140]), and progenitors with transcriptomic features of pDCs emerge prior to lymphoid progenitors ([@bib166]). Collectively, the results so far suggest that pDCs develop primarily through a Flt3L-driven pathway shared with cDCs, with a potential additional contribution from lymphoid progenitors. Importantly, clonal tracing studies of transplanted or cultured progenitors ([@bib54], [@bib96], [@bib99], [@bib116]) suggest that the commitment to produce pDC and/or cDC subsets may be determined at early stages of differentiation, i.e., prior to the emergence of phenotypically defined DC progenitors.

The fact that Flt3L alone is sufficient for pDC development suggests the existence of a robust transcriptional program that drives spontaneous pDC differentiation and pDC versus cDC lineage bifurcation, unless subverted by competing stimuli. Transcription factors such as PU.1 control the entire Flt3L-driven program of DC development ([@bib28]), whereas the subsequent specification of pDCs requires the E protein transcription factor TCF4 (E2-2) ([@bib36], [@bib114]). TCF4 is expressed in all hematopoietic progenitors and can amplify its own expression in developing pDCs through a BRD protein-dependent feedback loop, underlying a self-sustained program of pDC development ([@bib64]). The pDC expression program appears to be initiated in progenitors that express IRF8 ([@bib166]), which is required for pDC development *in vitro* (although surprisingly, not *in vivo* \[[@bib147]\]). TCF4 acts jointly with its protein cofactor MTG16 ([@bib61]) and additional factors such as BCL11A ([@bib76], [@bib176]) to promote pDC development ([Figure 1](#fig1){ref-type="fig"} A). Conversely, E protein inhibitor ID2 may "break" the TCF4-driven transcriptional program to channel the development into cDCs, particularly the ID2-dependent cDC1 subset. Thus, the loss of MTG16 or of transcriptional repressor ZEB2 ([@bib144], [@bib177]) causes de-repression of ID2 and impairs pDC development, whereas the development of cDC1 is enhanced. A milder reduction of TCF4 activity by the deletion of pDC-specific "long" isoform TCF4~L~ ([@bib64]) reduces pDC development but facilitates the development of the non-canonical DC subset discussed below. TCF4 is a close homolog of other E protein transcription factors TCF3 (E2A) and TCF12 (HEB), the key regulators of lymphocyte development. All three E proteins bind to the same consensus sequence and share target genes; accordingly, TCF4 in pDCs binds to and activates many genes that are activated by E2A/HEB in developing lymphocytes ([@bib30], [@bib61]). This unique feature of transcriptional control distinguishes pDCs from cDCs and likely accounts for their transcriptomic similarity to lymphoid progenitors ([@bib72]). For instance, Dntt (TdT) and Ccr9 are canonical targets of E proteins in lymphoid progenitors and are also among the most TCF4-dependent genes in murine pDCs ([@bib36]), even though Dntt has no obvious function in these cells. Furthermore, deletion of TCF4 from mature pDCs induces the switch to dendritic morphology and expression of cDC gene signature ([@bib30], [@bib60]). Additional "resolution" between pDC and cDC expression programs is provided by transcription factor ETV6, which represses the cDC gene signature in pDCs and vice versa ([@bib91]). Altogether, these studies underscore a close relationship between pDC and the cDC lineages and reveal a unique transcriptional program that maintains pDCs in a "lymphoid-like" state and opposes alternative cDC fates.Figure 1Transcriptional Control of pDC LineageTranscription factors with enriched expression in pDCs, cDCs, or all DCs are shown in red, blue, or violet, respectively.(A) Transcription factors that regulate pDC specification in the bone marrow. Lineage splits leading to alternative cell fates including cDC1s and non-canonical DCs are highlighted. TCF4~L~ denotes the pDC-specific long isoform of TCF4.(B) Transcription factors that regulate the differentiation of committed pDCs in the bone marrow and pDC functionality in the periphery.

Following the initial lineage commitment, pDCs undergo an elaborate differentiation program that ensures their functionality ([Figure 1](#fig1){ref-type="fig"}B). Thus, transcription factor SPIB facilitates the retention of immature pDCs in the BM ([@bib137]); conversely, RUNX2 facilitates the exit of mature pDCs from BM to the periphery ([@bib35], [@bib139]). The IFN-I-producing capacity of pDCs is dependent on interferon response family (IRF) transcription factors including IRF7 ([@bib74]), IRF5 ([@bib42], [@bib178]), and IRF8 ([@bib147]). Consistent with the key role of IRF7, several factors were shown to regulate its activity in pDCs: for instance, SPIB ([@bib137]) and NFATC3 ([@bib13]) interact with IRF7 and facilitate the activation of IFN-I genes. Furthermore, RUNX2 was proposed to directly activate IRF7 expression ([@bib35]) whereas MYC may repress it to limit IFN-I production ([@bib83]). Finally, pDC-enriched epigenetic regulator CXXC5 together with DNA demethylase Tet2 was shown to promote *Irf7* expression by maintaining the hypomethylation of its promoter in pDC ([@bib106]). Collectively, these studies begin to reveal a complex transcriptional network that maintains the capacity of pDCs for rapid response while limiting unwanted hyperactivation. Key parts of this network, including epigenetic mechanisms and *cis*-regulatory elements that facilitate pDC functionality, still remain to be identified.

Heterogeneity and Post-activation Fate of pDCs {#sec1.3}
----------------------------------------------

Recent single-cell analysis of human DC population revealed a subset with some phenotypic features of pDCs that was incapable of IFN-I production but efficiently primed T cells ([@bib3], [@bib145], [@bib169]). Together with other reports on human pDC heterogeneity ([@bib111], [@bib183]), these results suggest the existence of a "non-canonical" DC population that is intermediate between the canonical pDCs and cDCs. Further analysis of this population, defined by several markers including AXL, revealed that it is heterogeneous and comprises "pDC-like" as well as "cDC-like" cells ([@bib3], [@bib169]). Importantly, "non-canonical" DC subsets have been described previously in the mouse, most notably the distinct Cx3cr1^+^ subset of CD8^+^ cDCs ([@bib14], [@bib90]). These cells manifest the surface phenotype and functionality of cDCs, lack IFN-I production, yet have a transcriptional profile related to pDCs and require TCF4 for development. Furthermore, a recently deposited study proposed a distinct minor subset of Axl^+^ murine pDCs that are derived from lymphoid progenitors, lack IFN-I production, but show increased antigen-presenting capacity ([@bib50]). Preliminary comparison of expression profiles and/or phenotypes of these subsets suggests a concordance between human and murine "non-canonical" pDC and cDC subsets, which potentially comprise an evolutionarily conserved spectrum ([Figure 2](#fig2){ref-type="fig"} ). Notably, non-canonical pDCs and cDCs co-express TCF4 and ID2, consistent with their intermediate position between TCF4^hi^ pDCs and ID2^hi^ cDCs. This proposed cross-species alignment of DCs is supported by high-dimensional DC phenotyping in humans and mice (J. Idoyaga, personal communication) and remains to be comprehensively tested in future studies. Most importantly, the developmental origin and function of non-canonical subsets need to be elucidated in both species.Figure 2The Proposed Spectrum of Dendritic Cell SubsetsShown on this hypothetical scheme are canonical pDCs and cDCs (including cDC1 and cDC2) and the intermediate "non-canonical" populations including non-canonical pDCs (nc-pDC) and cDCs (nc-cDC). Shown are functional properties including the IFN-I production capacity and antigen presentation capacity in the steady state, expression of key transcription factors, and surface markers in the human ([@bib3], [@bib169]) and mouse ([@bib14], [@bib90], [@bib50]). Italicized genes and markers denote expression based on reported transcript levels.

Within the canonical mature pDC subset, heterogeneity is evident from the expression of surface markers such as murine CD4, CD8 ([@bib118]), or Ccr2 ([@bib139]), yet its significance remains unclear. The question of pDC heterogeneity is directly tied to a broader question of pDC function and eventual fate upon TLR-mediated activation. While activated pDCs are capable of cytokine production as well as antigen presentation and cross-presentation, these processes may either occur sequentially in the same cells or represent separate fates of different pDCs. The latter appears more likely because only a fraction of pDCs produce IFN-I irrespective of the stimulus, as confirmed using IFN-I reporter strains ([@bib17], [@bib86], [@bib165]). Furthermore, pDC activation results in the massive pDC apoptosis caused by IFN-I ([@bib157]). It is therefore conceivable that the majority of IFN-producing pDCs die *in vivo*, whereas the surviving ones remain capable of antigen presentation. Indeed, *in vitro* activated human pDCs generate distinct populations with preferential IFN-producing or antigen-presenting capacities ([@bib4]). These populations were proposed to diversify spontaneously through paracrine cytokine signaling; however, pre-existing commitment toward these fates within the pDC population cannot be ruled out. Importantly, the observed differentiation into cDC-like cells represents an intrinsic property of activated pDCs ([@bib66]) that cannot be explained by contamination with AXL^+^ DCs ([@bib3], [@bib4]). The analysis of such activation-induced differentiation *in vivo*, as well as the broad characterization of pDC cell fate during immune responses, represent important challenges for future studies.

Mechanism of Interferon Production by pDCs {#sec1.4}
------------------------------------------

Signaling by endosomal TLRs through the adaptor MyD88 and transcription factor IRF7 appears to be a major (albeit not exclusive) mechanism of pDC activation that results in IFN-I production ([@bib73], [@bib74]). Another consequence of TLR/MyD88 signaling is the activation of NF-κB and the ensuing induction of cytokines (such as TNF-α) and costimulatory molecules; this pathway is very important but not unique to pDCs and will not be further discussed here. Non-endosomal MyD88-dependent TLRs such as TLR2 may also be functional in pDCs in response to certain stimuli ([@bib45]). The cGAS/STING and RIG-I pathways of intracellular sensing may be functional in pDCs in response to replicating DNA viruses ([@bib98]) and RNA viruses ([@bib23], [@bib87]), respectively. Although it has been suggested that intracellular sensing pathways such as cGAS/STING and MDA5/MAVS may restrict IFN-I response of pDCs ([@bib179]), this model is not supported by other studies ([@bib153]). Importantly, endosomal TLR-induced IFN-I production represents a very specific feature of pDCs: for example, *in vivo* administration of TLR9 ligand CpG induces a rapid systemic IFN-I response that is mediated exclusively by pDCs ([@bib9], [@bib18], [@bib33]).

This, however, opens up a truly challenging question: what makes the TLR7/9-induced IFN-I response so specific for pDCs? The expression of TLR7 and TLR9 is a distinct but not unique property that is shared with B cells and several myeloid cell types (particularly in the mouse). Additional important mechanisms of TLR-induced IFN-I production include the PI3K/mTOR pathway activation ([@bib26], [@bib68]), prolonged retention of TLR ligands in early endosomes ([@bib67], [@bib73]), and regulation of endosomal TLR signaling by the AP-3 adaptor complex and the AP-3-interacting cation transporter Slc15a4 ([@bib21], [@bib136]). However, none of these mechanisms or molecules is specific for pDCs; conversely, candidate pDC-specific signaling mediators such as endocytic adaptor Pacsin1 contribute to IFN-I response but are not essential for it ([@bib56]). Finally, fundamental differences may exist in the response of pDCs to synthetic TLR agonists and to viruses: for instance, AP-3 was recently shown to be required for the former but not the latter ([@bib165]).

In most cell types, the expression of IRF7 is normally low or absent and is induced by the first wave of IFN-β production through an IFN-I receptor (IFNAR)-mediated feedback loop. Quiescent pDCs express high levels of IRF7 and therefore were proposed to secrete IFN-I rapidly and independently of the IFNAR-based feedback signaling ([@bib15], [@bib44]). Indeed, IFNAR was shown to be dispensable for pDC response to viruses such as vesicular stomatitis virus (VSV) ([@bib15]) and murine cytomegalovirus (MCMV) ([@bib165]). Surprisingly, IFNAR-deficient pDCs manifested normal response to MCMV despite expressing low baseline levels of IRF7 ([@bib165]). On the other hand, IFNAR appears necessary for full-strength IFN-I response to TLR ligands *in vivo* ([@bib10], [@bib21], [@bib165]) and to certain viruses *in vitro* ([@bib87]), and for optimal functionality of human pDC *in vitro* ([@bib92]). These data suggest that IFNAR-independent signaling does not require high IRF7 levels and may promote pDC responses to certain viruses, although full pDC functionality still requires intact IFNAR signaling.

In contrast to the traditional "cell-intrinsic" view of pDC activation, recent studies highlighted its unexpectedly cooperative nature ([Figure 3](#fig3){ref-type="fig"} A). It has been observed early on that pDC form tight clusters within hours of activation by TLR ligands *in vivo* ([@bib10]), although the functional significance of such clustering remained unclear. *In vitro*, the magnitude of IFN-I response to TLR ligands was shown to be facilitated by cell density ([@bib82]), as confirmed recently by single-cell activation assay ([@bib172]). These studies ascribed the observed cooperativity to autocrine/paracrine IFN-I signaling, which may indeed be important in these settings as discussed above. However, another potentially important mechanism is cell-cell interaction and the associated polarization of IFN-I production and sensing, as observed upon pDC activation *in vitro* ([@bib134]). This study showed that pDC response to TLR ligands and to the influenza virus is impaired in the absence of integrin LFA-1 and of downstream regulators of intracellular trafficking that localize TLRs and secreted IFN-I to the sites of cell-cell contact ([@bib134]). The contribution of LFA-1 expressed on pDCs to IFN-I production in response to MCMV and to TLR9 ligand has been recently confirmed *in vivo* ([@bib165]). These recent studies highlight cell-cell interactions (including homotypic clustering of pDCs) and the associated profound polarization of TLR sensing, IFN-I production, and IFN-I-mediated feedback signaling as important features of pDC response. Collectively, the unique IFN-I-producing capacity of pDCs cannot be easily explained by any single known mechanism or molecule. Instead, it appears to integrate multiple pathways and cellular processes, in a manner that still remains to be fully elucidated.Figure 3The Mechanism of pDC Activation(A) Activation by TLR ligands or viruses that do not infect pDCs. Shown is the traditional "cell-intrinsic" model and the emerging "cooperative" model that highlights homotypic interaction between pDCs and directional signaling and IFN secretion.(B) Activation by viruses that infect and replicate in pDCs. Shown is the "cell-intrinsic" model based on autophagy-mediated TLR signaling, and the proposed "cooperative" model whereby virus replication and TLR signaling occur in different cells, and TLR ligands are transferred via exosomes or viral particles. An infected cell is highlighted in dark gray.(C) Activation by viruses that infect cells other than pDCs. TLR ligands are transferred from infected cells (highlighted in dark gray) to pDCs during polarized contact via exosomes or viral particles.

Negative Regulation of IFN-I Production by pDCs {#sec1.5}
-----------------------------------------------

The IFN-I-producing capacity and "trigger-happy" state of pDC must have necessitated the need for counterbalancing inhibitory mechanisms. Some of these act through broadly expressed surface receptors such as CXCR4 and CD44, which inhibit pDC activation in response to natural monoamines ([@bib152]) and galectin-9 ([@bib123]), respectively. Several inhibitory receptors are shared with lymphocytes and seem to be "re-purposed" for inhibitory function in pDCs, such as murine Lag3 ([@bib175]) and CD28 ([@bib108]). Yet other receptors are relatively specific for pDCs, such as murine SiglecH and human BDCA-2 (CD303) and ILT-7 (CD85). Additional members of this class are likely to exist, as illustrated by the recent description of mouse pDC-specific inhibitory receptor CD300c ([@bib79]). These receptors inhibit pDC response when engaged with agonistic antibodies and are thought to signal through a common pathway involving ITAM-containing adaptors such as Fc receptors and DAP12 ([@bib62]). SiglecH is a sialic acid-binding lectin whose exact ligands are poorly understood, although its deletion causes enhanced IFN-I response by pDCs ([@bib125], [@bib143]). SiglecH-deficient mice also develop autoimmunity several weeks after viral infection ([@bib143]), although it is unclear whether this striking phenotype emanates from pDCs. Unless some pDCs acquire a long lifespan after infection, the delayed autoimmunity is likely mediated by long-lived SiglecH^+^ cells such as macrophages. BDCA-2 is a C-type lectin that binds multiple glycoproteins including serum immunoglobulins ([@bib84]), raising the possibility that antibody responses inhibit pDC activation through BDCA-2-mediated homeostatic mechanism. ILT-7 is an immunoglobulin-like receptor whose single known ligand is BST2 (tetherin), an interferon-inducible antiviral membrane protein that may provide a negative feedback signal to IFN-I-producing pDC ([@bib27]). Murine pDCs lack an obvious ortholog of ILT-7 but specifically express Bst2 ([@bib20]), which paradoxically facilitates IFN-I production ([@bib158]) and may contribute to pDC resistance to infection.

The species-specific nature of above-mentioned inhibitory pathways likely reflects separate evolutionary pressures from pathogens. On the other hand, a distinct and evolutionarily conserved pDC-specific pathway involves a receptor-type protein tyrosine phosphatase PTPRS, which is expressed in multiple tissues but is highly pDC-specific within the immune system of humans and mice ([@bib24]). The deletion or ligation of PTPRS (along with the homologous pDC-specific phosphatase PTPRF in the mouse) respectively enhanced or inhibited pDC activation. The ligands of PTPRS likely involve diverse heparan sulfate proteoglycans, suggesting a potential way for pDCs to monitor the integrity of extracellular matrix. The intracellular substrates of PTPRS are unknown, but the inhibitory activity of a tyrosine phosphatase mirrors the recently identified positive roles of tyrosine kinases SYK ([@bib7]), LYN, and FYN ([@bib43]) in pDC activation. Global or dendritic cell-specific deletion of PTPRS/PTPRF in the mouse caused spontaneous IFN-I production and colitis ([@bib24]), highlighting the inherent danger posed by even mild pDC hyperactivation. Overall, negative regulation of pDC responses appears fundamental to pDC biology and is responsible for the most prominent cell type-specific molecular features, including the hallmark surface markers such as SiglecH and BDCA-2. Further analysis of these pathways may provide attractive opportunities for therapeutic targeting of pDC activation, e.g., inhibition in autoimmune diseases or activation in cancer.

The Nature of Virus Recognition by pDCs {#sec1.6}
---------------------------------------

pDCs were defined by their ability to respond to the purified influenza virus added to cultures, and this certainly represents an important mode of pathogen recognition by these cells ([Figure 3](#fig3){ref-type="fig"}A). Direct recognition of internalized virions through endosomal TLRs is indeed strongly supported by the ability of pDCs to respond to viruses that have been rendered replication-deficient, e.g., by physical inactivation ([@bib8], [@bib48], [@bib87], [@bib104]). It is also consistent with the relative resistance of pDCs to infection by many viruses to which they are capable of responding with IFN-I production.

Other viruses such as VSV elicit IFN-I production only when replication-active ([@bib75], [@bib94]), and productive infection of pDCs by IFN-I-inducing viruses has been described *in vitro* ([@bib31], [@bib42], [@bib110]) and *in vivo* ([@bib107]). Notably, these experimental settings utilized high viral doses *in vitro*, and the resulting infection of pDCs was still lower than of other cell types. Autophagy may represent one mechanism whereby a virus replicating inside the pDC would get access to the endosomal compartment and induce IFN-I production ([Figure 3](#fig3){ref-type="fig"}B; [@bib94]). On the other hand, single-cell analysis of response to several viruses (including VSV) demonstrated that viral replication and IFN-I production occurs in different cells within the pDC population ([@bib48], [@bib52], [@bib58]). This may reflect the heterogeneity of IFN-I response by pDCs as noted above---in this scenario, IFN-I-producing pDCs would suppress viral replication while those lacking IFN-I production would sustain it. Another possibility, however, is that pDCs spontaneously "divide the labor"---some get infected and others recognize the virus replicating in the infected pDCs ([Figure 3](#fig3){ref-type="fig"}B). This scenario is consistent with the highly cooperative nature of pDC activation as discussed above, as well as with the emerging unique feature of pDCs: the ability to recognize virus-infected cells.

This new paradigm of virus recognition by pDCs ([Figure 3](#fig3){ref-type="fig"}C) was introduced in a study of hepatitis C virus (HCV), an RNA virus with a strict tropism for hepatocytes. It showed that pDCs produce IFN-I by interacting with and recognizing HCV-infected hepatocytes rather than the free HCV ([@bib162]). This recognition is TLR7 dependent, requires physical contact between pDCs and live infected cells, and was initially proposed to occur via the short-range transfer of viral RNA in exosomes ([@bib53], [@bib162]). Subsequent studies have demonstrated the same phenomenon for multiple diverse RNA viruses including retroviruses ([@bib97], [@bib132]), lymphocytic choriomeningitis virus (LCMV) ([@bib171]), hepatitis A virus ([@bib57]), Dengue and West Nile viruses ([@bib49]), and yellow fever vaccine virus ([@bib23]). These studies also showed that RNA of a replicating virus may be transferred between infected cells and pDCs within immature viral particles or enveloped virions. In cells latently infected with the DNA herpesvirus Epstein-Barr virus (EBV), EBV-derived RNA can be transferred to pDCs through exosomes and can elicit the expression of IFN-I and interferon-stimulated genes (ISG) ([@bib12]). In addition to human pDCs, this phenomenon was also observed in murine ([@bib58]) and porcine ([@bib59]) pDCs. It may also be applicable to non-viral pathogens, as suggested by the close interactions of pDCs with macrophages during TLR7-mediated activation of pDCs in malaria-infected mice ([@bib153]).

The recognition of virus-infected cells by pDCs has multiple potential advantages. First, it helps pDCs detect the virus during the main intracellular events of its life cycle including replication and possibly even latency, rather than during the often brief and rare extracellular transit. Indeed, the recognition of a free virus such as VSV, even at a high multiplicity of infection, appears less efficient than the recognition of cells infected with the same virus ([@bib58]). Second, it makes pDCs resistant to multiple evasion mechanisms used by viruses to prevent recognition and IFN-I secretion by the infected cell. Third, it allows the detection of viruses with a very narrow tropism (e.g., HCV) and facilitates precise tissue localization of responses toward infected cells. This mode of recognition also offers a potential explanation for the above-mentioned cases where pDCs themselves get infected: in this scenario, infected pDCs may elicit TLR-driven production of IFN-I from uninfected pDCs ([Figure 3](#fig3){ref-type="fig"}B). Thus, pDCs appear to have evolved a unique ability to monitor the intracellular compartment in a manner resembling other sentinel cells such as NK cells and cytotoxic T cells.

Fundamental questions still remain about this emerging mechanism of virus recognition by pDCs. Is the recognition of virus-infected cells a special case of certain viruses recognized through TLR7, or a "default" mode applicable to the majority of RNA and DNA viruses? TLR9-mediated recognition of infected cells has not been demonstrated yet, although the transfer of the virus and cellular material from cells infected with the DNA virus herpes simplex virus (HSV) to pDCs has been described ([@bib112]). Recent histological analysis of IFN-I-producing pDCs during MCMV infection suggests that they are indeed localized in proximity to virus-infected cells ([@bib165]). However, the recognition of primary infected cells by pDCs still remains to be documented *in vivo*, ideally by intravital microscopy. Perhaps most importantly, we need to understand how the virus-derived material is being transferred and why it can be recognized so efficiently compared to the free virus. The role of LFA-1-mediated adhesion in the process would be consistent with the analysis of homotypic pDC interactions ([@bib134]) and is supported by blocking studies *in vitro* ([@bib11], [@bib59]) and by genetic deletion *in vivo* ([@bib165]). These and other data support the formation of integrin-mediated "interferogenic synapse" between the infected cell and a pDC, as proposed in a recently deposited study ([@bib11]). Future studies should elucidate molecular mechanisms that mediate the formation and function of this synapse at both sides, particularly those responsible for its specificity for pDCs.

The Role of pDCs in Immune Responses to Infections {#sec1.7}
--------------------------------------------------

Studies of pDC activation *in vitro* typically demonstrate satisfyingly robust and specific responses of pDCs to the majority of viruses. However, *in vivo* testing of pDC function during infections has been frequently disappointing: for instance, pDCs are not strictly required for the *in vivo* control of such "model" murine viruses as influenza, VSV, MCMV, or acute LCMV ([@bib33], [@bib156], [@bib174]). These results may reflect the notoriously multilayered nature of immune responses---for instance, conventional DC were shown to compensate for the absence of pDCs in infections with ectromelia virus ([@bib80]) or MCMV ([@bib126]). Additional reasons may include peculiarities of laboratory mice as a model, such as the mutations of key antiviral ISG in common strains. Conversely, the role of pDCs has to be rigorously assessed by genetic ablation, as depleting or inactivating antibodies ([Table 1](#tbl1){ref-type="table"} ) are not fully pDC specific: for instance, the commonly used depletion target Bst2 (120G8, CD317, mPDCA-1) is also expressed on plasmacytes in the steady state and is induced on many cell types during infection ([@bib20]). Ultimately, genetic models using human BDCA2-driven diphtheria toxin receptor (DTR) for acute depletion ([@bib156]) or *Tcf4* targeting for constitutive pDC loss ([@bib33]) ([Table 1](#tbl1){ref-type="table"}) revealed several viral infections in which pDCs play a major non-redundant role. Although these tools implicated pDCs in response to certain non-viral pathogens such as bacteria ([@bib40]) and apicomplexan parasites ([@bib153], [@bib179]), the net activity of pDCs in these models appears complex and incompletely understood.Table 1*In vivo* Depletion and Functional Modulation of pDCsDriver/TargetTargeting StrategyAdvantagesCaveatsReferences**Genetic (Mouse)**Tcf4 (E2-2)DC-specific deletion using Itgax-Creconstitutive specific depletion of peripheral pDCscomplex allele combination; depletion incomplete on C57BL/6 background[@bib36], [@bib33]Tcf4 (E2-2)monoallelic germline deletionconstitutive functional impairment of pDCs; single allelepartial reduction of pDC numbers and functionality; effects in non-pDCs formally possible[@bib36], [@bib151]Ikzf1 (Ikaros)germline hypomorphic mutation on Rag2-null backgroundspecific absence of peripheral pDCscomplex allele combination; requires lymphocyte reconstitution; effects in non-pDCs formally possible[@bib6], [@bib69]CLEC4C (BDCA-2)human transgene driving DTRDT-inducible depletion; efficient; repeated DT injections used for several weeks; single alleletransient; side effects of DT[@bib156], [@bib131]SiglecHknock-in of DTRDT-inducible depletion; efficient; based on endogenous mouse genenonspecific effects in non-pDCs demonstrated; concomitant SiglecH deletion; side effects of DT[@bib161], [@bib160]**Antibody-Mediated (Mouse)**Bst2 (CD317)depleting mAb (clones 120G8, mPDCA-1, 927)rapid depletiontransient; can be used only in the steady state; targets other cells (e.g., plasma cells)[@bib9], [@bib85], [@bib20]SiglecHagonistic mAb (clone 440c)rapid functional impairmenttransient; may affect other cells (e.g., macrophages)[@bib18], [@bib19]**Antibody-Mediated (Human, Primate)**IL-3Rα (CD123)depleting mAb (clone CSL362)efficient depletiondepletes other CD123^+^ cells (e.g., basophils); blocks IL-3 signaling[@bib121]CLEC4C (BDCA-2, CD303)agonistic mAb (clone 24F4A)specific; causes functional impairmentefficiency to be demonstrated in human subjects[@bib124][^1]

Mouse hepatitis virus (MHV) causes an acute infection that is normally controlled in a TLR7- and IFNAR-dependent manner. A strict requirement for pDCs in the control of MHV infection has been demonstrated using both antibody-mediated and genetic pDC depletion ([@bib31], [@bib33]). Within 2 days post-infection, pDCs produce nearly all detectable IFN-I, which is critical for the survival of cDCs and macrophages ([@bib32]). Another prominent example of pDC dependence is systemic (but not local) HSV infection, in which pDC are required for early production of IFN-I within 8--12 h, NK cell activation, and ultimately for survival ([@bib159]). Using a complementary genetic approach in which IRF7-dependent IFN-I production was restricted to pDCs, it was shown that pDCs are sufficient to control acute infection with dengue and chikungunya viruses ([@bib170]). In all these models, a very rapid production of IFN-I by pDCs appears critical for protection against cytopathic effects of the virus, NK cell activation, amplification of cytokine response, and overall innate control of viral replication. Notably, systemic IFN-I production is not always detectable ([@bib170]), suggesting that close-range IFN-I production by pDCs may be particularly important. Given that coronaviruses, herpesviruses, and flaviviruses (exemplified by MHV, HSV, and dengue virus, respectively) exerted major evolutionary pressures on mammalian immune systems, these results emphasize the critical role of pDCs in immunity and explain their emergence and evolutionary conservation.

In addition to their innate protective function, pDCs also play a key role in shaping the adaptive responses to viruses. This was first illustrated by impaired survival and accumulation of VSV-specific cytotoxic T cells upon pDC depletion ([@bib156]). Moreover, pDC-deficient mice are unable to control persistent LCMV infection due to impaired CD4^+^ T cell priming, which in turn impairs CD8^+^ T cell response to LCMV ([@bib33]). The role of pDCs in T cell priming may be mediated at least in part through their cooperation with cDC ([@bib129]), particularly the recruitment of XCR1^+^ cDC1s that mediate CD8^+^ T cell cross-priming ([@bib22]). The effect of pDCs on T cell responses is not limited to cytotoxic T cell priming and may exert broader effects on virus-induced pathology. For example, pDCs contribute to IFN-I response and control of respiratory syncytial virus (RSV) infection in the lung ([@bib46], [@bib105]). In addition, they dampen RSV-induced Th2 cell responses, lung inflammation, and asthma ([@bib39]), at least in part through the induction of regulatory T (Treg) cells ([@bib105]). Likely reflecting the role of pDCs in long-term adaptive responses, persistent viruses such as LCMV impair the IFN-I producing capacity of pDCs ([@bib95], [@bib184]). This "exhausted" state of pDCs was recently shown to result from a combination of impaired development, enhanced self-renewal in the periphery, and persistent signaling through TLR7 ([@bib109]). The role of pDCs in human persistent viral infections has been largely studied in the HIV infection, where pDCs mount vigorous IFN-I response that is protective at early stages but may drive immune pathology later in the course of infection ([@bib2]). Collectively, these results highlight the critical dual function of pDCs in antiviral responses: (1) rapid protection through innate mechanisms such as cytoprotective effects and NK cell activation; (2) fine-tuning of adaptive responses through enhanced T cell differentiation. Both phenomena are likely to involve IFN-I production (both local and systemic) as well as other mechanisms such as production of additional cytokines and chemokines and possibly antigen presentation; elucidating these mechanisms represents an important challenge for years to come.

The Role of pDC Activation in Autoimmunity {#sec1.8}
------------------------------------------

Soon after pDCs were conclusively identified as a distinct IFN-I-producing cell type, their potential role in excessive cytokine production in autoimmune disease was proposed ([@bib130]). In subsequent years, excessive or aberrant pDC activity has been implicated in almost every autoimmune or inflammatory disease. As in the case of infections, rigorous testing in genetic models appears critical to define immune pathologies with a particularly prominent role of pDCs. For instance, genetic ablation of pDCs revealed only a mild stage-specific role of pDCs in a genetic model of psoriasis ([@bib63]) and no involvement in a chemically induced model ([@bib173]). In other examples, genetic impairment of pDCs had no effect in two genetic models of colitis ([@bib141]) and exacerbated the disease in an antibody-mediated model of arthritis ([@bib117]). Even genetic approaches occasionally produce conflicting results as illustrated by studies in atherosclerosis, where constitutive or inducible pDC ablation was shown to impair ([@bib133]) or promote ([@bib180]) the disease, respectively. On the other hand, recent genetic studies strongly support the pathogenic role of pDCs in several autoimmune diseases.

The role of pDCs in type I diabetes was proposed based on the expansion of pDCs at the onset of human diabetes ([@bib5]) and pDC infiltration into islets in the NOD mouse model ([@bib51]). Indeed, constitutive genetic depletion of pDCs was shown to ameliorate insulitis and significantly reduce the incidence of diabetes in NOD mice ([@bib71]). In scleroderma (systemic sclerosis, SSc), an antibody-mediated autoimmune disease that targets connective tissue including the skin, patients manifest the elevated expression of multiple ISGs ("interferon signature") and the pathogenic immune complexes induce IFN-I production in pDCs ([@bib55], [@bib81]). Moreover, pDCs from SSc patients produce high levels of proinflammatory hemokine CXCL4, which correlates with the risk and progression of the disease ([@bib167]). The most recent study connected the aberrant CXCL4 production to increased IFN-I expression in pDCs from SSc patients and showed that transient pDC depletion could prevent and even revert skin fibrosis in a chemically induced animal model ([@bib1]). In both diabetes and SSc, pDC likely act locally at the sites of inflammation (pancreatic islets and skin, respectively) and/or in the regional lymphoid organs to promote inflammation through the production of IFN-I and other mediators such as CXCL4.

Perhaps the strongest case for the pathogenic role of pDCs has been built in systemic lupus erythematosus (SLE), a systemic disease driven by immune complexes of autoantibodies and nucleic acid-containing nuclear antigens (reviewed in [@bib122]). More than half of SLE patients manifest interferon signature that correlates with clinical disease, and IFNAR deletion ameliorates SLE in experimental models. Clinical SLE is associated with the reduction of pDCs in the peripheral blood and their concomitant accumulation in tissue lesions. pDCs can be induced to produce IFN-I by multiple SLE-associated molecular features including nucleic acid-containing immune complexes, complexes of DNA with antimicrobial peptides, neutrophil extracellular traps (NETs), and as shown most recently, oxidized mitochondrial DNA ([@bib25], [@bib102]). Consistent with the predominant occurrence of SLE in females, female pDCs have higher IFN-I-producing capacity than male pDCs, due to both cell-intrinsic and -extrinsic factors ([@bib65], [@bib89]). Importantly, even a transient DTR-based ablation of pDCs ameliorated SLE in genetic models ([@bib47], [@bib131]). Furthermore, a constitutive impairment of pDCs by monoallelic deletion of *Tcf4* strongly reduced autoantibody production and all disease manifestations in two different spontaneous models of SLE ([@bib151]). The magnitude of the effect was particularly striking, given that *Tcf4* haplodeficiency causes only a partial reduction of pDC numbers and IFN-I-producing capacity. These data confirmed an essential role of pDCs in SLE pathogenesis as well as revealed its systemic nature: pDCs are required not only for inflammation triggered by immune complexes, but also for the production of autoantibodies. This emerging role of pDCs in both innate and adaptive immune responses to self is reminiscent of their dual role in antiviral responses as discussed above, and poses major questions about its mechanism. It remains to be determined what initial molecular signals cause pDC hyperactivation, and how they are sensed; the issue is particularly challenging because TLR9, the proposed major sensor of self-DNA in pDCs, appears to have a net tolerogenic activity in experimental SLE. Interestingly, the mechanism of sensing in some cases may resemble the recognition of virus-infected cells, e.g., the recognition of microRNA transferred via exosomes ([@bib135]). Another question is whether pDCs act primarily through IFN-I secretion (local or systemic), the production of other soluble mediators such as IL-6 ([@bib77]), or other functions such as antigen presentation. Finally, pDCs may act directly on the differentiation or maintenance of autoreactive B cells and/or promote autoreactivity indirectly through T cells or other cell types; the former possibility is supported by studies in human cells *in vitro* ([@bib77], [@bib113]) and remains to be confirmed and analyzed *in vivo*.

The Role of Impaired pDC Activity in Immunodeficiency and Cancer {#sec1.9}
----------------------------------------------------------------

Mirroring pDC hyperactivation in autoimmunity, impaired pDC activity has been implicated in immunodeficient states or inefficient immune responses, e.g., to tumors. pDCs in neonates have a significantly reduced capacity to produce IFN-I in response to viruses such as RSV ([@bib39], [@bib182]) and rhinovirus ([@bib16]). This reduced pDC function may contribute to increased susceptibility to infections in neonates and in particular may underline the ability of RSV to promote lung inflammation and asthma later in life ([@bib105]). On the other end of the age spectrum, pDCs from aged mice showed a significant impairment of IFN-I production *in vitro* and during viral infection *in vivo*, potentially due to increased oxidative stress ([@bib154]); a similarly impaired function was observed in pDCs from elderly humans ([@bib78]). Together with pDC impairment by persistent viruses as discussed above, the likely cell-extrinsic effect of aging on pDCs may contribute to impaired responses to infections and vaccines in the elderly.

Finally, studies in cancer patients showed a profoundly aberrant and/or hypofunctional state of tumor-infiltrating pDCs: in particular, pDCs in breast and ovarian tumors produce IFN-I poorly yet have an increased capacity to induce Treg cell differentiation ([@bib38], [@bib88], [@bib149]). This aberrant function may be imparted by tumor-derived soluble factors such as TGF-β ([@bib150]) and is thought to promote tumor growth as suggested by animal models ([@bib93]). The role of TGF-β and the tumor-promoting properties of pDCs have been recently supported by genetic pDC depletion in mice ([@bib164]). Although activated pDCs can be administered to elicit anti-tumor T cell responses *in vivo* ([@bib101], [@bib163]), the data so far suggest a net tumor-promoting effect of endogenous pDCs that manifest impaired IFN-I production and immunosuppressive properties. The molecular basis of pDC reprogramming in the tumor environment remains to be fully elucidated and may represent a target for immunotherapy.

Concluding Remarks {#sec1.10}
------------------

Based on the knowledge of pDC biology accumulated over the last two decades, it should now be possible to address major outstanding issues, such as the molecular basis of IFN-I-producing capacity of pDCs, the nature and consequences of pathogen recognition, and the mechanisms whereby pDCs contribute to protective and pathogenic immune responses. Moreover, the field seems to be rapidly crossing the "bottleneck" toward translation of the basic knowledge into clinically relevant applications. For example, the study of pDC development helped elucidate a highly aggressive leukemia type, the blastic plasmacytoid dendritic cell neoplasm (BPDCN), from its initial identification as the leukemic counterpart of pDCs ([@bib34]) to better diagnostic tools and potential therapeutic approaches targeting pDC-specific transcriptional machinery ([@bib30]). Furthermore, the analysis of pDC function led to the development of antibodies that deplete pDCs or inhibit their function ([Table 1](#tbl1){ref-type="table"}). Further dissection of pDC regulation should facilitate the development of non-depleting reagents to modulate pDC function in the long term, e.g., dampen pDC hyperactivation in autoimmunity or reverse their dysfunction in cancer. The observations that even a partial functional modulation ([@bib71], [@bib151]) or a transient ablation ([@bib1], [@bib131]) of pDCs have a dramatic effect on chronic disease bode well for the utility of this cell type as a therapeutic target.
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[^1]: Abbreviations: DT, diphtheria toxin; DTR, diphtheria toxin receptor; mAb, monoclonal antibody.
